US Bioservices is now dispensing RITUXAN HYCELA

June 27, 2017

The U.S. Food and Drug Administration has approved RITUXAN HYCELA (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with specific forms of lymphoma and leukemia.